447 related articles for article (PubMed ID: 28710747)
1. Phase I study of chimeric antigen receptor modified T cells in treating HER2-positive advanced biliary tract cancers and pancreatic cancers.
Feng K; Liu Y; Guo Y; Qiu J; Wu Z; Dai H; Yang Q; Wang Y; Han W
Protein Cell; 2018 Oct; 9(10):838-847. PubMed ID: 28710747
[TBL] [Abstract][Full Text] [Related]
2. [In vitro and in vivo validation of cytotoxicity of targeting human epidermal growth factor receptor-2 chimeric antigen receptor T (HER2-CAR-T) cells].
Zhang Y; Xi W; Wang P; Zhao X; Zheng R; Liang S; Meng R; Yan B; Yang A
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2024 Apr; 40(4):289-295. PubMed ID: 38710512
[TBL] [Abstract][Full Text] [Related]
3. Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells.
Nellan A; Rota C; Majzner R; Lester-McCully CM; Griesinger AM; Mulcahy Levy JM; Foreman NK; Warren KE; Lee DW
J Immunother Cancer; 2018 Apr; 6(1):30. PubMed ID: 29712574
[TBL] [Abstract][Full Text] [Related]
4. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma.
Hegde M; Joseph SK; Pashankar F; DeRenzo C; Sanber K; Navai S; Byrd TT; Hicks J; Xu ML; Gerken C; Kalra M; Robertson C; Zhang H; Shree A; Mehta B; Dakhova O; Salsman VS; Grilley B; Gee A; Dotti G; Heslop HE; Brenner MK; Wels WS; Gottschalk S; Ahmed N
Nat Commun; 2020 Jul; 11(1):3549. PubMed ID: 32669548
[TBL] [Abstract][Full Text] [Related]
5. Simulating the Evolution of Signaling Signatures During CART-Cell and Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
Annu Int Conf IEEE Eng Med Biol Soc; 2023 Jul; 2023():1-5. PubMed ID: 38083755
[TBL] [Abstract][Full Text] [Related]
6. CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer.
Qi C; Xie T; Zhou J; Wang X; Gong J; Zhang X; Li J; Yuan J; Liu C; Shen L
J Hematol Oncol; 2023 Sep; 16(1):102. PubMed ID: 37689733
[TBL] [Abstract][Full Text] [Related]
7. CAR-T Cell Therapy in Pancreatic and Biliary Tract Cancers: An Updated Review of Clinical Trials.
Drougkas K; Karampinos K; Karavolias I; Gomatou G; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Kotteas E
J Gastrointest Cancer; 2024 May; ():. PubMed ID: 38695995
[TBL] [Abstract][Full Text] [Related]
8. Targeting ERBB2/HER2 genetic alterations: an expanding therapeutic opportunity in gastrointestinal cancers.
Zheng-Lin B; Graham RP; Bekaii-Saab TS
Chin Clin Oncol; 2023 Oct; 12(5):55. PubMed ID: 37964543
[TBL] [Abstract][Full Text] [Related]
9. Autologous HER2-specific CAR T cells after lymphodepletion for advanced sarcoma: a phase 1 trial.
Hegde M; Navai S; DeRenzo C; Joseph SK; Sanber K; Wu M; Gad AZ; Janeway KA; Campbell M; Mullikin D; Nawas Z; Robertson C; Mathew PR; Zhang H; Mehta B; Bhat RR; Major A; Shree A; Gerken C; Kalra M; Chakraborty R; Thakkar SG; Dakhova O; Salsman VS; Grilley B; Lapteva N; Gee A; Dotti G; Bao R; Salem AH; Wang T; Brenner MK; Heslop HE; Wels WS; Hicks MJ; Gottschalk S; Ahmed N
Nat Cancer; 2024 Apr; ():. PubMed ID: 38658775
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY; Stuckert A; Tat C; White M; Ruggieri L; Zhang H; Mehta B; Lapteva N; Mei Z; Major A; Thakkar S; Shum T; Parikh K; Wu MF; Lindsay HB; Scherer L; Shekar M; Baxter P; Wang T; Grilley B; Moeller K; Hicks J; Roy A; Anastas J; Malbari F; Aldave G; Chintagumpala M; Blaney S; Parsons DW; Brenner MK; Heslop HE; Rooney CM; Omer B
J Clin Oncol; 2024 May; ():JCO2302019. PubMed ID: 38771986
[TBL] [Abstract][Full Text] [Related]
11. Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology.
Manne A; Woods E; Tsung A; Mittra A
Front Oncol; 2021; 11():768009. PubMed ID: 34868996
[TBL] [Abstract][Full Text] [Related]
12. Simulating the Evolution of Signaling Signatures during CART-Cell - Tumor Cell Interactions.
Shah V; Womack J; Zamora AE; Terhune SS; Dash RK
ArXiv; 2023 Feb; ():. PubMed ID: 36798455
[TBL] [Abstract][Full Text] [Related]
13. The Role of HER2 Status in the Biliary Tract Cancers.
Ayasun R; Ozer M; Sahin I
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174094
[TBL] [Abstract][Full Text] [Related]
14. Editorial: Biomarkers and immunotherapy of hepatic-biliary-pancreatic cancers.
Qian Y; Jia W; Liu H
Front Oncol; 2023; 13():1301416. PubMed ID: 37941545
[No Abstract] [Full Text] [Related]
15. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Chimeric Antigen Receptor-Modified T Cells in Patients with EGFR-Positive Advanced Biliary Tract Cancers.
Guo Y; Feng K; Liu Y; Wu Z; Dai H; Yang Q; Wang Y; Jia H; Han W
Clin Cancer Res; 2018 Mar; 24(6):1277-1286. PubMed ID: 29138340
[No Abstract] [Full Text] [Related]
17. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
[TBL] [Abstract][Full Text] [Related]
18. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
[No Abstract] [Full Text] [Related]
19. Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Tchou J; Zhao Y; Levine BL; Zhang PJ; Davis MM; Melenhorst JJ; Kulikovskaya I; Brennan AL; Liu X; Lacey SF; Posey AD; Williams AD; So A; Conejo-Garcia JR; Plesa G; Young RM; McGettigan S; Campbell J; Pierce RH; Matro JM; DeMichele AM; Clark AS; Cooper LJ; Schuchter LM; Vonderheide RH; June CH
Cancer Immunol Res; 2017 Dec; 5(12):1152-1161. PubMed ID: 29109077
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
